Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Enasidenib - Celgene

Drug Profile

Enasidenib - Celgene

Alternative Names: AG 221 mesylate; AG-221; AGI 12910 mesylate; AGI-12910; CC-90007; IDHIFA

Latest Information Update: 09 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agios Pharmaceuticals
  • Developer Agios Pharmaceuticals; Celgene Corporation; Massachusetts General Hospital
  • Class Antineoplastics; Propanols; Pyridines; Small molecules; Triazines
  • Mechanism of Action Isocitrate dehydrogenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase II Myelodysplastic syndromes
  • Phase I/II Solid tumours
  • Phase I Chronic myelomonocytic leukaemia

Most Recent Events

  • 09 Dec 2019 Updated efficacy and adverse events data from a phase I/II trial in Acute myeloid leukaemia released by Celgene Corporation
  • 20 Nov 2019 Celgene Corporation has been acquired by Bristol-Myers Squibb
  • 19 Sep 2019 University Health Network in collaboration with Celgene and AbbVie plans a phase Ib/II ENAVEN-AML trial for IDH2-Mutated Myeloid malignancies including Acute-myeloid-leukemia and Myelodysplastic-syndromes (Combination therapy, Second-line therapy or greater) in Canada (PO) (NCT04092179)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top